Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294.
A new bioactive compound of the N-acylhydrazone class, LASSBio-294, was shown to produce a cardioinotropic effect and vasodilation. In this study, we report the structure-based drug metabolism prediction, biosynthesis and identification of the major mammalian metabolite of LASSBio-294.